^
BIOMARKER:

EGFR exon 19 deletion

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive
:
A1
J Cancer Res Clin Oncol - 3 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
KN046
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
erlotinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
erlotinib + ramucirumab
Sensitive
:
A1
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive
:
A2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR inhibitor
Sensitive
:
B
EGFR exon 19 deletion
Lung Adenocarcinoma
gefitinib
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
icotinib
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib + rivoceranib
Sensitive
:
B
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
B
EGFR exon 19 deletion
Lung Adenocarcinoma
afatinib
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib + ramucirumab
Sensitive
:
B
EGFR exon 19 deletion
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
aumolertinib
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
furmonertinib
Sensitive
:
B
EGFR exon 19 deletion
Lung Adenocarcinoma
osimertinib
Sensitive
:
C1
EGFR exon 19 deletion
Small Cell Lung Cancer
gefitinib
Sensitive
:
C1
EGFR exon 19 deletion
Lung Cancer
gefitinib
Sensitive
:
C1
EGFR exon 19 deletion
Small Cell Lung Cancer
osimertinib
Sensitive
:
C1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib + gefitinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
anlotinib + icotinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGF816
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
amivantamab-vmjw + lazertinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
U3-1402
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
bevacizumab + osimertinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
tislelizumab
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
bevacizumab
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
lazertinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
BBT-176
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive
:
C3
EGFR exon 19 deletion
Non Small Cell Lung Cancer
erlotinib + anlotinib
Sensitive
:
C3
EGFR exon 19 deletion
Non Small Cell Lung Cancer
rivoceranib + camrelizumab
Resistant
:
C3